- Home
- About
- Find staff
- Peter Larsson
Peter Larsson
Postdoctor
Department of Laboratory MedicineAbout Peter Larsson
Peter Larsson defended his doctoral thesis in the research subject of Oncology, June 13, 2023
The title of his thesis is – The proteasome as a target for cancer therapy
-
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological
cancers
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2024 -
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor
properties
Peter Larsson, MC Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2024 -
Repurposing proteasome inhibitors for improved treatment of triple-negative breast
cancer
Peter Larsson, Daniella Pettersson, Maxim Olsson, Sithumini Sarathchandra, Alexandra Abramsson, Henrik Zetterberg, Ella Ittner, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Cell death discovery - 2024 -
Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in
vitro
Maxim Olsson, Peter Larsson, Junko Johansson, Vasu R. Sah, Toshima Z Parris
Frontiers in Cell and Developmental Biology - 2023 -
The proteasome as a target for cancer
therapy
Peter Larsson
2023 -
Optimization of Cell Viability Assays for Drug Sensitivity
Screens.
Peter Larsson, Toshima Z Parris
Methods in molecular biology (Clifton, N.J.) Vol. 2644 - 2023 -
Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer
types.
Peter Larsson, Daniella Pettersson, Hanna Engqvist, Elisabeth Werner Rönnerman, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
BMC cancer - 2022 -
Pan-cancer analysis identifies BIRC5 as a prognostic
biomarker.
Anna Fäldt Beding, Peter Larsson, Khalil Helou, Zakaria Einbeigi, Toshima Z Parris
BMC Cancer - 2022 -
Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma
histotypes.
Hanna Engqvist, Toshima Z Parris, Jana Biermann, Elisabeth Werner Rönnerman, Peter Larsson, Karin Sundfeldt, Anikó Kovács, Per Karlsson, Khalil Helou
Scientific reports - 2020 -
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity
screens.
Peter Larsson, Hanna Engqvist, Jana Biermann, Elisabeth Werner Rönnerman, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2020